Comparative Pharmacology
Head-to-head clinical analysis: AMANTADINE versus DENAVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMANTADINE versus DENAVIR.
AMANTADINE vs DENAVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.
DENAVIR is a synthetic peptide that inhibits viral replication by preventing the fusion of the viral envelope with the host cell membrane. It specifically targets the HIV-1 envelope glycoprotein gp41, blocking the conformational changes required for membrane fusion.
100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).
5 mg applied topically to affected area once daily for 4 weeks.
None Documented
None Documented
Clinical Note
moderateAmantadine + Haloperidol
"The therapeutic efficacy of Haloperidol can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Mifepristone
"Amantadine may increase the QTc-prolonging activities of Mifepristone."
Clinical Note
moderateAmantadine + Promazine
"The therapeutic efficacy of Promazine can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Chlorpromazine
Terminal elimination half-life: 10-14 hours in young adults, up to 24 hours in elderly; prolonged to >24 hours in renal impairment
Terminal elimination half-life is 2.5–3.5 hours in patients with normal renal function. Prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 90% as unchanged drug via glomerular filtration and tubular secretion; fecal: <10%
Renal excretion of unchanged drug accounts for approximately 90% of the administered dose via glomerular filtration and tubular secretion. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
Antiviral / Antiparkinsonian
Antiviral
"The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Amantadine."